R&D Insights on Zealand's GLP-1/GLP-2 Drug Phase 1b Data
Monday, 9 September 2024, 08:45
Zealand Pharma's GLP-1/GLP-2 dual agonist has revealed new hope in its Phase 1b clinical trial. Previously challenged by lower dosing efficacy concerns, this innovative treatment showcased promising weight loss results, paving the way for future developments in R&D.
The early-stage trial data indicates that the drug effectively promotes weight reduction, reinstating confidence in its potential therapeutic benefits.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.